...
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Posts by Jitendra

Home » Articles Posted by Jitendra (Page 24)
01 Oct
Press Release

Scilex Announces New Medicaid Agreements with CA & FL

  • July 15, 2021
  • Posted by Jitendra
PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its subsidiary, Scilex Pharmaceuticals, Inc., (together, with...

Read more

30 Sep
Press Release

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

  • July 15, 2021
  • Posted by Jitendra
PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in...

Read more

23 Sep
Press Release

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft registration statement on Form S-1...

Read more

15 Apr
Press Release

Scilex Semnur Corporate Presentation

  • July 15, 2021
  • Posted by Jitendra
DOWNLOAD PRESENTATION

Read more

27 Mar
Press Release

Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

  • July 15, 2021
  • Posted by Jitendra
Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. sciatica All subjects experienced rapid reduction of...

Read more

22 Mar
Press Release

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

  • July 15, 2021
  • Posted by Jitendra
Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA With non-opioid ZTlido, RTX, and SP102 commercial and near-commercial product lines, Sorrento and its subsidiaries...

Read more

14 Jan
Press Release

Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8%...

Read more

14 Jan
Press Release

Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by...

Read more

20 Sep
Press Release

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

  • July 15, 2021
  • Posted by Jitendra
SAN DIEGO, September 19, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO)...

Read more

07 Sep
Press Release

Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation

  • July 15, 2021
  • Posted by Jitendra
Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles Pain SAN DIEGO, September 7, 2018 – Scilex Pharmaceuticals...

Read more

«‹2223242526›»
Close
Recent Posts
  • Nasdaq_Gloperba03
    Gloperba Launch – Nasdaq-2024
    July 10, 2024 No Comments
  • A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain
    June 14, 2024 No Comments
  • Gout Awareness Day – May 22
    May 20, 2024 No Comments
  • Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
    March 14, 2024 No Comments
  • Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch
    March 14, 2024 No Comments

scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2024 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info